Skip to main content

Tesofensine

Source index · review incomplete

An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.

Source summary generated July 17, 2026; this date does not indicate completed review.

Cognitive Enhancement185 cited mentions
Track your own protocol free →

Quotes from three independent practitioners, with their sources. Research context only.

What it is and how it works

From the published literature on Tesofensine; the papers are listed at the end. Research summary, not a recommendation.

What it is

Tesofensine (development code NS2330) is a synthetic small molecule, not a peptide, from the phenyltropane family, developed by the Danish company NeuroSearch. It was first tested in people with Parkinson's and Alzheimer's disease, where it did not improve the diseases but produced unintended weight loss, so development switched to obesity. It is not approved by the FDA or the European Medicines Agency; a partner company applied for approval in Mexico, which had not been granted in the latest company updates found as of 2026-11-06.

How it works

Tesofensine blocks the reuptake of three brain messengers, dopamine, noradrenaline and serotonin, so more of each stays active between nerve cells; this makes it a 'triple monoamine reuptake inhibitor'. In obese rats, its appetite-suppressing effect depended on indirect stimulation of alpha-1 adrenergic and dopamine D1 receptors. In a human metabolism study it strongly increased fullness and reduced hunger and slightly raised energy expenditure at night and fat burning. In mice, it quieted a population of hunger-promoting GABA nerve cells in the lateral hypothalamus.

What it has been studied for

  • Weight loss in obesity (phase 2 randomized trial)
  • Appetite and energy expenditure in overweight men (randomized trial)
  • Early Parkinson's disease (randomized trial, no benefit)
  • Weight loss observed in Parkinson's and Alzheimer's trials (pooled analysis)
  • Appetite circuits in the brain (rat and mouse studies)

Strength of the evidence

Human trialsRandomized phase 2 trials in obesity and neurological disease have been published; published phase 3 data were not found, and it is not approved in the US or Europe.

What the literature reports on safety

In trials, tesofensine raised resting heart rate, and the most common side effects were dry mouth, insomnia, nausea, constipation and diarrhoea; higher doses brought more mood and sleep complaints. Blood pressure was not significantly raised at the lower doses in the obesity trial, but rose significantly at the highest dose tested. It is not approved in the United States or Europe, and products sold online under its name are unregulated.

Key papers

  1. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity (opens in a new tab)

    Review · Bello NT, Zahner MR · Current Opinion in Investigational Drugs (2009) · PMID 19777399

    Reviewed tesofensine's development from a Parkinson's and Alzheimer's candidate into an obesity drug acting on three monoamine transporters.

  2. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial (opens in a new tab)

    Randomized trial · Astrup A, Madsbad S, et al. · Lancet (2008) · PMID 18950853

    In a phase 2 trial in obese adults, tesofensine produced substantially more weight loss than placebo over 24 weeks, raised heart rate, and needed confirmation in phase 3 trials.

  3. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men (opens in a new tab)

    Randomized trial · Sjödin A, Gasteyger C, et al. · International Journal of Obesity (2010) · PMID 20479765

    In overweight men, tesofensine strongly reduced appetite and slightly increased night-time energy expenditure and fat burning compared with placebo.

  4. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease (opens in a new tab)

    Review · Astrup A, Meier DH, et al. · Obesity (2008) · PMID 18356831

    A pooled analysis of Parkinson's and Alzheimer's trials found tesofensine caused weight loss without diet changes and raised heart rate without changing blood pressure.

  5. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease (opens in a new tab)

    Randomized trial · Hauser RA, Salin L, et al. · Movement Disorders (2007) · PMID 17149725

    In early Parkinson's disease, tesofensine gave no significant benefit over placebo, while weight loss and raised heart rate were common.

  6. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat (opens in a new tab)

    Animal study · Axel AM, Mikkelsen JD, Hansen HH · Neuropsychopharmacology (2010) · PMID 20200509

    In obese rats, tesofensine suppressed feeding through indirect stimulation of alpha-1 adrenergic and dopamine D1 receptor pathways.

  7. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons (opens in a new tab)

    Animal study · Perez CI, Luis-Islas J, et al. · PloS One (2024) · PMID 38656972

    In mice, tesofensine silenced GABA nerve cells in the lateral hypothalamus that promote eating, independent of taste aversion.

Sources checked: PubMed/PMC (E-utilities esearch, esummary and abstracts on every PMID), company news on the Mexican application, written 2026-11-06.

Hunter Williams

→ profile

Protocol systematizer

Sources: compound titles first, then mentions

Taylor Williams

→ profile

Female-focused HRT + peptides

4 earlier videos were removed from YouTube; titles kept for the record

Ask the Tesofensine Librarian

Answers are generated from captured sources and may omit context or contain errors. Check the supporting passages.

What have the teachers said about Tesofensine? Ask what it is, what they say it does, or where they discuss it. Questions about doses or personal use: ask your own clinician.

AI chat. To generate a reply, your question and recent chat history may be processed by Cloudflare Workers AI, Groq, Google Gemini or OpenRouter, depending on availability. Keep personal health details out of the chat and check the cited sources. Research use only; not medical advice.

Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.

Disclaimer: for research purposes only

All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.

Tesofensine — Hunter, Taylor, Bachmeyer | Reset Biology